Some analysts are making calls and projections on Moderna that in my view are minimalistic into the beginning and end of 2023.
I view some of these analysts as no better at predicting where the share will this year and the prospect for 2022 no better than what the environment informs current owners to what is occurring in the world and inform reports from the medical experts and the company's CEO and management. Bottom line Moderna continues to be a very inexpensive stock even though it has risen 300% whereby another 450%+ upside continues to remain for the share price to rise.$Moderna, Inc.(MRNA)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
